Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23581880 | 1.00 | HSD17B10 (0.53) | HSD17B10MAPK1KMT2AALDH1A1HPGD | |
| SCHEMBL16528509 | 0.85 | SMN1; SMN2 (0.54) | HSD17B10MAPK1KMT2AALDH1A1HPGD | |
| SCHEMBL26077366 | 0.83 | SMN1; SMN2 (0.50) | HSD17B10KMT2AMEN1SMN1; SMN2CYP2C9 | |
| SCHEMBL29244762 | 0.82 | ACKR3 (0.51) | HSD17B10KMT2AMEN1 | |
| SCHEMBL23871348 | 0.82 | ACKR3 (0.51) | HSD17B10KMT2AMEN1 | |
| SCHEMBL21605864 | 0.82 | ACKR3 (0.51) | HSD17B10KMT2AMEN1 | |
| SCHEMBL21193355 | 0.79 | HSD17B10 (0.48) | HSD17B10MAPK1KMT2AALDH1A1HPGD | |
| SCHEMBL2069052 | 0.78 | FEN1 (0.48) | HSD17B10KMT2AALDH1A1HPGDGAA | |
| SCHEMBL4043389 | 0.78 | CA12 (0.43) | HSD17B10MAPK1KMT2AALDH1A1HPGD | |
| SCHEMBL25241327 | 0.77 | HSD17B10 (0.49) | HSD17B10MAPK1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261210-B1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | MSD KK (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8367698-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | NAGASE TSUYOSHI (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8188280-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | MSD K.K. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2261210-A1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | HSD17B10 1705/4885MAPK1 2516/4885KMT2A 869/4885 |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | HSD17B10 1705/4885MAPK1 2516/4885KMT2A 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.